Biosafety classification is based on U.S. Public Health Service Guidelines, it is the responsibility of the customer to ensure that their facilities comply with biosafety regulations for their own country.
Rockwell P, Goldstein NI. Monoclonal antibodies specific to VEGF receptors and uses thereof. US Patent 5,955,311 dated Sep 21 1999
Witte L, et al. Monoclonal antibodies targeting the VEGF receptor-2 (Flk1/KDR) as an anti-angiogenic therapeutic strategy. Cancer Metastasis Rev. 17: 155-161, 1998. PubMed: 9770111
Prewett M, et al. Antivascular endothelial growth factor receptor (fetal liver kinase 1) monoclonal antibody inhibits tumor angiogenesis and growth of several mouse and human tumors. Cancer Res. 59: 5209-5218, 1999. PubMed: 10537299
Shaheen RM, et al. Effects of an antibody to vascular endothelial growth factor receptor-2 on survival, tumor vascularity, and apoptosis in a murine model of colon carcinomatosis. Int. J. Oncol. 18: 221-226, 2001. PubMed: 11172585
Kadambi A, et al. Vascular endothelial growth factor (VEGF)-C differentially affects tumor vascular function and leukocyte recruitment: role of VEGF-receptor 2 and host VEGF-A. Cancer Res. 61: 2404-2408, 2001. PubMed: 11289105
Kozin SV, et al. Vascular endothelial growth factor receptor-2-blocking antibody potentiates radiation-induced long-term control of human tumor xenografts. Cancer Res. 61: 39-44, 2001. PubMed: 11196192
Zimmermann RC, et al. Preovulatory treatment of mice with anti-VEGF receptor 2 antibody inhibits angiogenesis in corpora lutea. Microvasc. Res. 62: 15-25, 2001. PubMed: 11421657
Klement G, et al. Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity. J. Clin. Invest. 105: R15-R24, 2000. PubMed: 10772661
Stoelcker B, et al. VEGF/Flk-1 interaction, a requirement for malignant ascites recurrence. J. Inferon Cytokine Res. 20: 511-517, 2000. PubMed: 10841080
